Preparation method and application of supramolecular solvent containing puerarin

Abstract

The invention relates to the technical field of cosmetics, in particular to a preparation method and application of a supramolecular solvent containing puerarin. The supramolecular solvent containing puerarin comprises puerarin, a hydrogen bond donor and a hydrogen bond receptor, the molar ratio of the hydrogen bond donor to the acceptor is (1-3): (1-2). The puerarin-containing supramolecular solvent formed by using weak interaction force such as hydrogen bonds can effectively solve the problems that puerarin is easy to separate out in the product and poor in transdermal absorption and the like, and meanwhile, the puerarin-containing supramolecular solvent can synergistically promote the effect of puerarin in the oil-control acne-removal product. Cosmetics prepared by adopting the supramolecular solvent prepared by the invention have good oil control and soothing effects, and the preparation process is simple, large-scale production is easy, and the properties are stable.

Description

Technical Field

[0001] The present invention relates to the technical field of cosmetics, and in particular to a preparation method and application of a supramolecular solvent containing puerarin. Background Art

[0002] Puerarin is an isoflavone compound extracted from Pueraria root, with significant anti-inflammatory, antioxidant, and sebum metabolism-regulating activities. Puerarin alleviates the inflammatory response caused by Propionibacterium acnes by inhibiting the release of inflammatory factors. Simultaneously, its antioxidant effect can reduce hair follicle blockage caused by sebum oxidation, thereby preventing the formation of acne. Furthermore, puerarin indirectly controls oil production by inhibiting excessive sebaceous gland secretion by regulating pathways such as PPARγ. However, traditional puerarin has poor water and fat solubility, resulting in insufficient bioavailability of puerarin in traditional dosage forms.

[0003] Acne vulgaris, a chronic inflammatory skin disease, has long plagued many people due to its multifactorial pathology, which involves abnormal keratinization of the sebaceous ducts of the hair follicles, excessive proliferation of Propionibacterium acnes, hypersecretion of sebum, and dysregulated inflammatory responses. According to the World Health Organization, over one billion people worldwide suffer from acne, with the prevalence among adolescents reaching as high as 85%. While existing treatments can alleviate acne, they still face a series of core challenges, including drug resistance and high skin irritation.

[0004] Acids remain a common and effective treatment for acne, both clinically and in cosmetic science. Mandelic acid and salicylic acid, classic hydroxy acids, have long been widely used in skin care due to their unique lipid solubility and keratin-regulating properties, playing a particularly important role in oil control and acne treatment. However, traditional hydroxy acids face significant limitations in skin care, such as salicylic acid's poor solubility and high irritation, and mandelic acid's difficulty in transdermal absorption. Therefore, addressing these solubility limitations remains a hot topic in the skin care field.

[0005] For example, Chinese patent CN112375075A discloses a method for extracting puerarin using a natural deep eutectic solvent. The method comprises adding kudzu root powder to an aqueous solution of the natural deep eutectic solvent, ultrasonically extracting the mixture at 20-75°C and 200W for 15-75 minutes, centrifuging, and collecting the supernatant to obtain a kudzu root extract containing puerarin. The natural deep eutectic solvent in the aqueous solution of the natural deep eutectic solvent is a mixture of a hydrogen bond donor, a hydrogen bond acceptor, and / or deionized water. This invention provides an efficient and green method for extracting puerarin using a natural deep eutectic solvent, with an extraction rate 79.2% higher than that of an aqueous extract. This method has the characteristics of short extraction time, low energy consumption, and environmental friendliness. By introducing a natural deep eutectic solvent to extract puerarin, this invention provides a new research and development approach for the extraction of active ingredients in traditional Chinese medicine.

[0006] For example, Chinese patent CN117682949A discloses a salicylic acid deep eutectic solvent, its preparation method, and application. The salicylic acid deep eutectic solvent is formed by combining salicylic acid, L-carnitine, and an optional polyol under intermolecular forces, which changes the molecular polarity in the salicylic acid deep eutectic solvent, enhances hydrogen bonding and van der Waals forces with water, increases the water solubility of salicylic acid, and improves the transdermal permeability of L-carnitine and salicylic acid. The resulting skin care products and toiletries do not require the addition of excessive excipients, have a good skin feel, are mild, and are non-irritating. The preparation method provided by this invention combines multiple deep eutectic solvent preparation methods during the preparation process. The reaction conditions are mild, the time required is short, and it is conducive to industrial production. The reaction is thorough, and the available range of multiple substances can be increased at the same time.

[0007] Therefore, there is an urgent need to develop a safe and non-irritating method that can improve the problems of poor solubility, easy precipitation, and difficult transdermal delivery of puerarin. Summary of the Invention

[0008] Based on the deficiencies in the prior art, the present invention aims to provide a preparation method and application of a supramolecular solvent containing puerarin.

[0009] To achieve the above technical objectives, the present invention is implemented through the following technical solutions:

[0010] In one aspect, the present invention provides a supramolecular solvent containing puerarin, comprising puerarin, a hydrogen bond donor, and a hydrogen bond acceptor.

[0011] Preferably, the hydrogen bond donor is at least two of glycerol, glucose, butylene glycol, propylene glycol, salicylic acid, mandelic acid, and malic acid;

[0012] Further preferably, the hydrogen bond donor is glycerol and salicylic acid or glycerol and mandelic acid.

[0013] Preferably, the hydrogen bond acceptor is at least one of betaine, choline chloride, and carnitine;

[0014] More preferably, the hydrogen bond acceptor is betaine or carnitine.

[0015] Preferably, the molar ratio of the hydrogen bond donor to the acceptor is 1-3:1-2.

[0016] Preferably, the mass proportion of puerarin in the supramolecular solvent is 5%-10%, preferably 9%-10%, and more preferably 9.09%.

[0017] On the other hand, the present invention also provides a method for preparing the supramolecular solvent containing puerarin, comprising the following steps:

[0018] (1) Weigh the hydrogen bond donor and hydrogen bond acceptor and mix them evenly;

[0019] (2) heating and stirring under inert gas protection to obtain a mixed solution;

[0020] (3) Under the protection of inert gas, add the ethanol solution of puerarin to the mixed solution obtained in step (2), heat and stir, ultrasonicate, and cool to obtain the product.

[0021] Preferably, the inert gas in step (2) is one of helium, argon or nitrogen, preferably argon.

[0022] Preferably, the pressure of the inert gas in step (2) is 5-20 MPa, preferably 10 MPa.

[0023] Preferably, the temperature of the heating and stirring in step (2) is 30-100° C., the speed of the heating and stirring is 50-200 rpm, and the time of the heating and stirring is 18-24 h.

[0024] Further preferably, the temperature of the heating and stirring in step (2) is 85° C., the speed of the heating and stirring is 200 rpm, and the time of the heating and stirring is 18 h.

[0025] Preferably, the ultrasonic treatment in step (3) has a power of 200-600 W and a frequency of 10-30 kHz, with ultrasound for 5 seconds followed by a pause of 5 seconds, for 1-3 hours.

[0026] Further preferably, the power of the ultrasonic treatment in step (3) is 200 W, the frequency is 20 kHz, and the ultrasonic treatment is performed for 5 seconds followed by a pause of 5 seconds, for 2 hours.

[0027] Preferably, the amount of ethanol added to the puerarin in step (3) is 5-10 mL, more preferably 9 mL.

[0028] Finally, the present invention also provides the use of the supramolecular solvent containing puerarin in the preparation of oil-controlling and acne-removing products.

[0029] Preferably, the product is a cosmetic or a medicine.

[0030] Preferably, the cosmetic is an anti-acne lotion, an anti-acne essence or an anti-acne cream.

[0031] Preferably, the mass percentage of the supramolecular solvent containing puerarin in the product is 0.1%-5%.

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] The present invention combines hydrogen bond acceptors and hydrogen bond donors in a certain ratio to generate weak intermolecular interactions with puerarin, such as hydrogen bonds and van der Waals forces. Furthermore, the hydrogen bond donors contain hydroxy acids such as salicylic acid, significantly improving the poor solubility, easy precipitation, and difficult transdermal delivery of puerarin and hydroxy acids. Furthermore, the supramolecular solvent contains a large number of hydrogen bond networks, which encapsulate the puerarin molecules, further reducing skin irritation caused by the sudden release of puerarin and hydroxy acids in the product. The present invention is simple to prepare and can be produced on a large scale, laying the foundation for the application of puerarin in pharmaceuticals and skin care applications. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 The supramolecular solvent prepared in Example 1 of the present invention 1 HNMR spectrum (abscissa: chemical shift f1 (ppm), ordinate: absorption intensity);

[0035] Figure 2 The supramolecular solvent prepared in Example 2 of the present invention 1 HNMR spectrum (abscissa: chemical shift f1 (ppm), ordinate: absorption intensity);

[0036] Figure 3 This is a statistical graph showing the toxic effects of the supramolecular solvent containing puerarin prepared in Example 1 of the present invention on HaCat cells;

[0037] Figure 4 This is a statistical graph showing the toxic effects of the puerarin-containing supramolecular solvent prepared in Example 1 of the present invention on RAW 264.7 cells;

[0038] Figure 5 This is a graph showing the cumulative permeation amount of the supramolecular solvent containing puerarin prepared in Example 1 of the present invention and ordinary puerarin in an in vitro transdermal diffusion experiment;

[0039] Figure 6 This is an experimental diagram showing the effect of the puerarin-containing supramolecular solvent prepared in Example 1 of the present invention on the IL-8 content;

[0040] Figure 7This is an experimental diagram showing the effect of the puerarin-containing supramolecular solvent prepared in Example 1 of the present invention on the IL-1α content;

[0041] Figure 8 This is an experimental diagram showing the effect of the puerarin-containing supramolecular solvent on TNF-α content obtained in Example 1 of the present invention.

[0042] Figure 9 This is a graph showing the exfoliation cell count of HaCat cells using the puerarin-containing supramolecular solvent prepared in Example 1 of the present invention;

[0043] Figure 10 This is an experimental diagram showing the effect of the puerarin-containing supramolecular solvent prepared in Example 1 of the present invention on the oil synthesis of SZ95 cells induced by linoleic acid. DETAILED DESCRIPTION

[0044] The technical solution of the present invention is described clearly and completely below with specific embodiments. Obviously, the embodiments described are only some embodiments of the present invention, rather than all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative work are within the scope of protection of the present invention. The materials, reagents, etc. used, unless otherwise specified, are reagents and materials available from commercial sources.

[0045] Basic Example 1 Preparation of Mandelic Acid-Based Supramolecular Solvents

[0046] The specific steps are:

[0047] (1) Take 100 g of mandelic acid, betaine, and water in a molar ratio of 1:1:3 and mix well;

[0048] (2) Under the protection of argon gas at a pressure of 10 MPa, heat to 85°C and stir until no obvious stratification occurs;

[0049] (3) Ultrasonic treatment with a power of 200 W, an ultrasonic frequency of 20 kHz, and a treatment time of 2 h yields a colorless to light yellow transparent liquid.

[0050] according to Figure 1 As shown, no covalent bonds are generated in the obtained liquid, and only weak interactions such as hydrogen bonds and van der Waals forces between molecules jointly promote the formation of supramolecular solvents.

[0051] Basic Example 2 Preparation of Salicylic Acid-Based Supramolecular Solvents

[0052] The specific steps are:

[0053] (1) Take salicylic acid, carnitine, glycerol, and water in a molar ratio of 1:2:2:6, totaling 100 g, and mix them evenly;

[0054] (2) Under the protection of argon gas at a pressure of 10 MPa, heat to 85°C and stir until no obvious stratification occurs;

[0055] (3) Ultrasonic treatment with a power of 200 W, an ultrasonic frequency of 20 kHz, and a treatment time of 2 h to obtain a light yellow transparent liquid.

[0056] according to Figure 2 As shown, no covalent bonds are generated in the obtained liquid, and only weak interactions such as hydrogen bonds and van der Waals forces between molecules jointly promote the formation of supramolecular solvents.

[0057] Example 1 Preparation of supramolecular solvent containing puerarin

[0058] The specific steps are:

[0059] (1) Take salicylic acid, carnitine, glycerol, and water in a molar ratio of 1:2:2:6, totaling 100 g, and mix them evenly;

[0060] (2) Under the protection of argon gas at a pressure of 10 MPa, heat to 85°C and stir until no obvious stratification occurs;

[0061] (3) Under argon atmosphere, add 9 mL of puerarin ethanol solution, start argon flow, heat and stir until the solution is transparent and clear; use ultrasonic treatment with a power of 200 W, an ultrasonic frequency of 20 kHz, and a treatment time of 2 h;

[0062] (4) Detecting the amount of residual ethanol, cooling the mixture until no ethanol remains, and obtaining a supramolecular solvent containing 9.09% by mass of puerarin.

[0063] Example 2 Preparation of supramolecular solvent containing puerarin

[0064] The specific steps are:

[0065] (1) Take 100 g of mandelic acid, betaine, and water in a molar ratio of 1:1:3 and mix well;

[0066] (2) Under the protection of argon gas at a pressure of 10 MPa, heat to 85°C and stir until no obvious stratification occurs;

[0067] (3) Under argon atmosphere, add 9 mL of puerarin ethanol solution, start argon flow, heat and stir until the solution is transparent and clear; use ultrasonic treatment with a power of 200 W, an ultrasonic frequency of 20 kHz, and a treatment time of 2 h;

[0068] (4) Detecting the amount of residual ethanol, cooling the mixture until no ethanol remains, and obtaining a supramolecular solvent containing 9.09% puerarin by mass.

[0069] Comparative Example 1

[0070] The difference from Example 1 is that the molar ratio of salicylic acid, carnitine, glycerol and water is 1:3:3:3; after cooling and dilution with water, a large amount of solid precipitation occurs, proving that the supramolecular solvent is not stable.

[0071] Comparative Example 2

[0072] The difference from Example 2 is that the molar ratio of mandelic acid, betaine and water is 4:1:3; after cooling and dilution with water, a large amount of solid precipitation occurs, proving that the supramolecular solvent is not stable.

[0073] Comparative Example 3

[0074] The only difference from Example 1 is that room temperature stirring is used in step (2); the results show that after stirring for 18 hours, there are still many solid particles in it, and a uniform and transparent supramolecular solvent has not been formed.

[0075] Comparative Example 4

[0076] The only difference from Example 1 is that ultrasonic treatment is not performed in step (3); the results show that the sample becomes turbid and begins to separate after 24 hours, and does not have long-term stability.

[0077] Application Example 1 Preparation of Anti-Acne Essence Containing Puerarin Supramolecular Solvent

[0078] (1) Add 1% glycerol, 3% butylene glycol, 0.5% p-hydroxyacetophenone, 0.6% hexylene glycol, 0.05% sodium acrylate copolymer, 0.05% sodium hyaluronate, 2% Tween-60 and the balance water to a 200 g beaker and heat at 80°C for 20 min.

[0079] (2) adding 2.5% by mass of squalane, 2% by mass of polyglycerol-3 methylglucose distearate, 0.5% by mass of jojoba seed oil, and 0.3% by mass of cetearyl alcohol, homogenizing at a speed of 7000 rpm for 3 min, and stirring to cool;

[0080] (3) When the temperature of the material body drops to 45° C., 1% by weight of the supramolecular solvent containing puerarin prepared in Example 1 and the balance of water are added, and the temperature is lowered to obtain the product.

[0081] Application Example 2 Preparation of Anti-Acne Water Containing Puerarin Salicylic Acid-Based Supramolecular Solvent

[0082] (1) Add 3% glycerol, 5% butylene glycol, 0.5% p-hydroxyacetophenone, 0.6% hexylene glycol, 0.05% sodium hyaluronate, 0.1% EDTA-2Na and the balance water to a 200 g beaker and heat at 80°C for 20 min.

[0083] (2) Homogenize at 7000 rpm for 3 min, stirring and cooling;

[0084] (3) When the temperature of the material body drops to 45° C., add 1% by weight of the supramolecular solvent containing puerarin prepared in Example 1 and the balance of water; and cool the material body to obtain the product.

[0085] Application Example 3 Preparation of Anti-Acne Cream Containing Puerarin Salicylic Acid-Based Supramolecular Solvent

[0086] (1) In a 200 g beaker, add 0.2% carbomer 940, 5% glycerol, 0.05% xanthan gum, 0.5% hexylene glycol, 0.5% p-hydroxyacetophenone, 0.05% sodium hyaluronate, 0.1% EDTA-2Na and the balance water, and heat at 80°C for 20 min.

[0087] (2) Add 6% by mass of isohexadecane, 2% by mass of shea butter, 1.5% by mass of C16-18 alcohol, 2% by mass of glyceryl stearate, and 0.5% by mass of PEG-100 stearate, homogenize at a speed of 9000 rpm for 5 minutes, and stir to cool.

[0088] (3) When the temperature of the material drops to 45° C., 0.15% by mass of arginine and 1% of the supramolecular solvent containing puerarin prepared in Example 1 and the balance of water are added, and the temperature is lowered to obtain the product.

[0089] Effect Experiment

[0090] 1. Cytotoxicity of supramolecular solvents containing puerarin

[0091] MTT assay was used to detect the cytotoxic effects of supramolecular solvents containing puerarin on HaCaT cells and RAW 264.7 cells. HaCaT or RAW 264.7 cells were cultured at a cell density of 8000 cells / cm 2 The cells were inoculated into 96-well plates. Different concentrations of the supramolecular solvent containing puerarin prepared in Example 1 and a physical mixture of puerarin-salicylic acid-carnitine-glycerol-water were co-cultured with HaCaT cells or RAW 264.7 cells for 48 h. MTT reagent was then added and incubated for 4 h. DMSO was then added and the absorbance of each group of cells was measured at 490 nm to calculate the cell survival rate (%). Figure 3 、 4 As shown, the results showed that the cell survival rate was not less than 85%, indicating that the supramolecular solvent containing puerarin had no cytotoxicity to HaCaT cells and RAW 264.7 cells and had good biosafety.

[0092] The cell viability calculation formula is as follows:

[0093]

[0094] Wherein, A represents the absorbance value, the negative control group is the absorbance of cells not treated with the drug, the blank control group is the absorbance of the 96-well plate itself, and the sample group is the absorbance of cells treated with the drug in Example 1.

[0095] 2. Cumulative permeation test of supramolecular solvent containing puerarin and ordinary puerarin in vitro transdermal diffusion experiment

[0096] The ex vivo skin of a Bama miniature pig with no surface damage was selected and cleaned with physiological saline. Then, the skin was fixed on a Franz diffusion cell with the stratum corneum facing upwards. PBS was added to the receiving cell, and after balancing for 30 minutes, the bubbles in the diffusion cell were removed by tapping with an ear bulb. The water bath temperature was set to 32±1°C, and 1g of the supramolecular solvent containing puerarin prepared in Example 1 was accurately weighed. The stirring speed of the receiving cell was set to 600rpm, and samples of the receiving cell were taken at 2h, 4h, 6h, 8h, 10h, 12h, and 24h. The samples were centrifuged at 12000rpm for 10min, and the supernatant was taken. After passing through a 0.22μm filter membrane, liquid phase detection was performed, and the cumulative permeation amount was calculated, as shown in FIG. Figure 5 The diameter of the diffusion cell is 20 mm, and the effective diffusion surface is approximately 3.14 cm. 2 .

[0097] The formula for calculating the cumulative transmittance is as follows:

[0098]

[0099] Among them, Q n is the cumulative permeation volume, V is the total volume of the receiving liquid, C n is the drug concentration in the receiving solution at the time of the nth sampling, C i is the mass concentration of the drug in the receiving solution at the time of sampling for the i-th time, V i is the sampling volume, and A is the effective diffusion area.

[0100] 3. Effects of supramolecular solvents containing puerarin on cellular inflammatory factors

[0101] RAW264.7 cells in logarithmic growth phase with good morphology were seeded in 24-well plates at a cell density of 2 × 10 cells per well. 5 pieces / cm 2 A blank control group, a stimulation group, and a sample group were set up and incubated in a 37°C, 5% CO2 incubator for 12 hours. Except for the blank control group, lipopolysaccharide LPS was added to each well for stimulation induction, and different concentrations of the supramolecular solvent containing puerarin prepared in Example 1 were added to the sample group and incubated for 24 hours. The contents of IL-1α, TNF-α, and IL-8 in the collected cell supernatants were detected respectively, and the inhibition rate of inflammatory factors of each group relative to the LPS-induced stimulation group was calculated. The results are shown in FIG. Figure 6 、 7 , 8. The results showed that within the safe concentration range, the supramolecular solvent containing puerarin had a significant inhibitory effect on cellular inflammatory factors.

[0102] 4. Counting HaCaT Cells by Using Puerarin-Containing Supramolecular Solvents

[0103] HaCaT cells in logarithmic growth phase with good morphology were seeded in 6-well plates at a cell density of 10 cells per well. 6 A blank control group (blank group) and Example 1 group were set up and incubated in a 37°C, 5% CO2 incubator for 12 hours. Except for the blank control group, different concentrations of supramolecular solvent containing puerarin were added to each well for incubation for 12 hours. The cell supernatant was taken and counted with a cell counter to obtain the number of exfoliated keratinocytes. Figure 9 As shown, the results showed that within the safe concentration range, the supramolecular solvent containing puerarin had an exfoliation effect on HaCaT cells.

[0104] 5. Skin patch irritation test of supramolecular solvent containing puerarin

[0105] Qualified patch test equipment was used, and an occluded patch test method was used. The supramolecular solvent containing puerarin prepared in Example 1 was diluted with purified water to a concentration of 3% as a sample group. Purified water was used in the negative control group. Approximately 0.020g-0.025g of each was placed in the patch test apparatus and applied to the inner arm of 32 subjects (aged 22-39, healthy) using hypoallergenic tape. The test substance was removed after 24 hours, and skin reactions were observed 0.5, 24, 48, and 72 hours after removal. The results were recorded according to the skin reaction grading standards in the "Safety Technical Specifications for Cosmetics" (2015 edition). The results are shown in Tables 1 and 2. The results show that in the human patch test, the 3% supramolecular solvent containing puerarin did not cause adverse skin reactions, indicating low irritation.

[0106] Table 1

[0107]

[0108] Table 2

[0109]

[0110]

[0111] 6. Effect of supramolecular solvent containing puerarin on lipid secretion of SZ95 cells induced by linoleic acid

[0112] SZ95 cells in logarithmic growth phase with good morphology were seeded in 96-well plates at a cell density of 8000 cells / cm2 A blank control group and a sample group were set up and incubated in a 37°C, 5% CO2 incubator for 12 hours. Except for the blank control group, linoleic acid was added to each well for stimulation and induction, and different concentrations of the supramolecular solvent containing puerarin prepared in Example 1 were added to the sample group and incubated for 24 hours. Nile red reagent was added for incubation, and the fluorescence intensity was tested using a multifunctional microplate reader. Figure 10 As shown, the results showed that the fluorescence intensity of the sample group added with the supramolecular solvent containing puerarin decreased significantly, proving that the supramolecular solvent containing puerarin can inhibit the oil synthesis of SZ95 cells induced by linoleic acid and has a good oil control effect.

[0113] 7. Stability test

[0114] Test sample: the sample prepared in Example 1.

[0115] Experimental methods:

[0116] Each test sample was tested under five test conditions, including -18°C, room temperature, light, 45°C, and -18-45°C hot and cold cycle (-18°C for 12 hours, 45°C for 12 hours), for 15 days, 30 days, 60 days, and 90 days. Each test sample was observed for significant changes. No change was considered qualified, and changes were considered unqualified. The test results are shown in Table 3 below. As can be seen from the results in Table 3, the supramolecular solvent containing puerarin prepared in Example 1 showed significant changes in appearance, pH, and color during the 90-day stability test, indicating good stability.

[0117] Table 3

[0118]

[0119]

[0120] The above detailed description is a specific description of one feasible embodiment of the present invention. This embodiment is not intended to limit the patent scope of the present invention. Any equivalent implementation or modification that does not depart from the present invention should be included in the scope of the technical solution of the present invention.

Claims

1. A supramolecular solvent containing puerarin, characterized in that: include: Puerarin, a hydrogen bond donor and a hydrogen bond acceptor; the molar ratio of the hydrogen bond donor to the acceptor is 1-3:1-2.

2. The supramolecular solvent according to claim 1, characterized in that The hydrogen bond donors are at least two of glycerol, glucose, butylene glycol, propylene glycol, salicylic acid, mandelic acid and malic acid.

3. The supramolecular solvent according to claim 1, characterized in that The hydrogen bond acceptor is at least one of betaine, choline chloride or carnitine.

4. The supramolecular solvent according to claim 1, characterized in that Calculated by mass fraction, the puerarin accounts for 5%-10% in the supramolecular solvent.

5. The method for preparing the supramolecular solvent according to any one of claims 1 to 4, characterized in that: The steps include: (1) Weigh the hydrogen bond donor and hydrogen bond acceptor and mix them evenly; (2) heating and stirring under inert gas protection to obtain a mixed solution; (3) Under the protection of inert gas, add the ethanol solution of puerarin to the mixed solution obtained in step (2), heat and stir, ultrasonicate, and cool to obtain the product.

6. The preparation method according to claim 5, characterized in that The inert gas in step (2) is one of helium, argon or nitrogen; the pressure of the inert gas is 5-20 MPa.

7. The preparation method according to claim 5, characterized in that The temperature of the heating and stirring in step (2) is 30-100° C., the speed of the heating and stirring is 50-200 rpm, and the time of the heating and stirring is 18-24 h.

8. The preparation method according to claim 5, characterized in that The ultrasonic treatment in step (3) has a power of 200-600W, a frequency of 10-30kHz, and lasts for 1-3h.

9. Use of the supramolecular solvent according to any one of claims 1 to 4 or the supramolecular solvent prepared by the preparation method according to any one of claims 5 to 8 in the preparation of oil-controlling and anti-acne products.

10. The use according to claim 9, characterized in that The product is a cosmetic or a medicine.

Images